Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

Figures & data

Table I. Patient characteristics.

Characteristic	n (%)
Age
<50	5 (8)
50–60	20 (31)
61–70	21 (33)
>70	18 (28)
Gender
Male	40 (63)
Female	24 (37)
Prior treatments for advanced RCC
Radiotherapy	35 (55)
IFNα	31 (45)
WHO performance status
0	38 (59)
≥1	26 (41)
Line of treatment
1^st	31 (48)
2^nd	24 (38)
≥3^rd	9 (14)
Time from initial diagnosis
≤12 months	38 (59)
>12 months	26 (41)
Prior nephrectomy
Yes	58 (91)
No	6 (9)
Number of organ sites affected
1	9 (14)
2	27 (42)
≥3	28 (44)

Table II. Systolic and diastolic blood pressure among patients requiring treatment or sunitinib-related hypertension.

Measure	Baseline mmHg, mean ± SD	At start of HTN therapy mmHg, mean ± SD	One month after start of HTN therapy mmHg, mean ± SD
SBP	137.4 ± 4.1	157.0 ±6.9	147.2 ±7.6
DBP	85.1 ± 3.1	100.6 ± 5.7	93.6 ± 4.2

Abbreviations: HTN, hypertension; SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure

Table III. Cox regression analysis of progression-free survival.

Variable	Hazard ratio for progression	95% CI	P
Pretreatment hemoglobin (normal vs. <normal)	1.06	0.36–3.09	0.91
Pretreatment calcium level (normal vs. <normal)	1.50	0.19–5.21	0.71
WHO performance status (0 vs. ≥1)	0.13	0.11–0.62	0.0064
Time from diagnosis to onset of metastasis (<12 vs. ≥ 12 months)	0.29	0.13–1.02	0.062
Treatment related hypertension (yes vs. no)	0.21	0.076–0.59	0.0030

Abbreviations: CI, confidence interval; WHO, World Health Organization.

Figure 1. Time to progression (Panel A) and overall survival (B) by hypertension treatment during sunitinib therapy.